Xoma | XOMA - Selling And Administration Expenses

Stock Price
37.90
Daily Change
0.01 0.03%
Monthly
25.50%
Yearly
57.00%
Q2 Forecast
37.09

Xoma reported $11M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Ardelyx USD 75.92M 7.69M Dec/2025
aTyr Pharma USD 82.26M 77.46M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Celldex Therapeutics USD 7.84M 1.21M Dec/2025
Curis USD 1.34M 3.45M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Incyte USD 390.41M 61.33M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Prothena USD 7.65M 5.59M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Xoma USD 11M 2.54M Jun/2024